INTRODUCTION
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour (NET) originating from the neural crest-derived parafollicular C cells and accounting may occur either sporadically or in a hereditary form as a component of the type 2 multiple endocrine 1 MTC is frequently an aggressive tumour with a high rate of metastatic 1 The pivotal role of imaging in MTC patients is -ment for MTC is surgical resection, which is the 1 Different morphological and functional imaging methods may be used in patients with MTC both in preoperative staging and for detecting persistent/recurrent disease 1 In the post-operative setting, conventional morphological imaging modalities can often be negative or inconclusive in the presence of rising serum levels of -fore, functional radionuclide imaging using different radiopharmaceuticals was explored as a way to detect persistent/recurrent MTC, though its role in the initial 2,3 Several radiopharmaceuticals evaluating different metabolic pathways or receptor status can be used as positron emission tomography (PET) tracers in detecting MTC lesions, including fluorine-18-fluorodeoxyglucose ( 18 F-FDG), fluorine-18-dihydroxyphenylalanine ( 18 F-DOPA) and [4] [5] [6] [7] [8] NETs usually overexpress somatostatin receptors on their cell surface and this represents the rationale for using several somatostatin analogues labelled with 68 Ga-DOTANOC, 68 Ga-DOTATOC or 68 Ga-DOTATATE) for the diagnosis -tor PET is a valuable diagnostic tool displaying high diagnostic performance in the majority of patients with [9] [10] [11] [12] [13] Nevertheless, experience with somatostatin receptor PET in recurrent MTC is limited compared to other articles have assessed the detection rate (DR) of PET using 15 and 18 F-DOPA 16, 17 in recurrent MTC, a meta-analysis evaluating the DR of somatoTherefore, we aimed to perform a systematic review and a meta-analysis on the DR of somatostatin receptor PET or PET/computed tomography (PET/CT) in patients with recurrent MTC to add evidence-based
METHODS
This meta-analysis was performed according to the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) statement which describes an evidence-based minimum set of items for 18 Furthermore, specific suggestions for meta-analyses
19

Search strategy
A comprehensive computer literature search of PubMed/MEDLINE and Cochrane Library Databases was conducted to find relevant published articles on the diagnostic performance of somatostatin receptor used a search algorithm that was based on a combination of these terms: A) medullary OR thyroid and b) -updated until May 31 st retrieved articles were also screened for additional
Study selection
Studies or subsets in studies investigating the diagnostic performance of somatostatin receptor PET in patients with recurrent MTC were eligible for inclusion in the qualitative analysis (systematic within the field of interest of this review; b) review articles, editorials or letters, comments, conference For the quantitative analysis (meta-analysis) we excluded studies with insufficient data to reassess the Two researchers (GT and AT) independently re-viewed the titles and abstracts of the retrieved articles, applying the inclusion and exclusion criteria mentioned -dently reviewed the full-text version of the remaining
Data extraction
For each included study, information was collected concerning basic study ( 
RESULTS
Literature search
The comprehensive computer literature search from PubMed/MEDLINE and the Cochrane Database 232 articles were excluded: 192 because not in the field of interest of this review, 29 as reviews, editorials or [21] [22] [23] [24] [25] [26] [27] [28] [29] No additional studies were found screening the references of these analysis (systematic review) were included in the quantitative analysis (meta-analysis) because all had sufficient data to assess the diagnostic performance - The diagnostic performance of somatostatin receptor PET in recurrent MTC was usually compared to that of other functional imaging techniques in this
In seven articles somatostatin receptor PET findings in recurrent MTC patients were compared with those of 18 F-FDG PET or PET/CT with conflicting [22] [23] [24] [25] [26] 28, 29 Most studies did not find any significant differences in the diagnostic performance of somatostatin receptor PET/CT and 18 F-FDG PET or PET/ CT; [23] [24] [25] [26] 29 only one study found a s ignificantly higher diagnostic performance of somatostatin receptor PET compared to 18 22 Only one study compared the diagnostic performance of somatostatin receptor PET/CT with 18 F-DOPA PET/CT in recurrent reporting a significantly lower Overall, somatostatin receptor PET or PET/CT seems not to accurately map the disease extent in patients with recurrent MTC; however, its provision of complementary information compared to other functional imaging techniques could be useful in identifying patients suitable for consideration of [21] [22] [23] [24] [25] [26] [27] [28] [29] 
Quantitative analysis (meta-analysis)
The DR of somatostatin receptor PET or PET/CT in patients with recurrent MTC on a per patient-analysis
The included studies were statistically quite heterogeneous in their estimate of DR (I 2 Performing a sub-analysis based on the type of study we found that the pooled DR of somatostatin receptor PET in prospective studies was slightly
The pooled DR of somatostatin receptor PET or PET/CT was also calculated in 66 patients with serum Ctn levels >500 ng/L with a pooled estimate [21] [22] [23] [24] [25] [26] [27] [28] [29] These studies have limited power, analyzing only relatively small robust estimates of diagnostic performance of somatostatin receptor PET in this setting we have pooled adopted in ascertaining studies and the quality of the included studies was assessed by using the 2011 Oxford Centre for Evidence-Based Medicine check- 20 We chose to use the DR as a measure of diagnostic performance of somatostatin receptor PET and PET/CT in patients with recurrent MTC in order to homogenize included in our meta-analysis were quite heterogeneous as regards the definition of false negative and true negative findings of somatostatin receptor PET: while some studies considered patients with increased serum Ctn levels and negative somatostatin receptor PET and other imaging methods as false negative results, conversely, other studies considered the same patients as true negative, thus partially contributing to the wide range of diagnostic performance that can problems because both false negative and true negative results are considered in the denominator using
The findings of our pooled analysis indicate that somatostatin receptor PET or PET/CT has a nonoptimal DR in patients with recurrent MTC on a per --current MTC cases would remain unidentified using considered that somatostatin receptor PET is usually performed in patients with recurrent MTC after management of a significant number of recurrent In order to study the factors which may influence the DR of somatostatin receptor PET in recurrent MTC, a sub-analysis considering serum Ctn values DR of somatostatin receptor PET in recurrent MTC in patients with serum Ctn > 500 ng/L), suggesting that this functional imaging method could be useful Serum Ctn doubling time is a useful marker of aggressiveness and progression rate in patients with -strated that the DR of Recent meta-analyses demonstrated a high diagnostic performance of somatostatin receptor PET or PET/CT in patients with NETs with sensitivity [10] [11] [12] [13] Overall, the diagnostic performance of somatostatin receptor PET or PET/CT in recurrent MTC seems to be inferior compared to other NETs due to the variable [30] [31] [32] [33] [34] Different PET tracers could be used in detecting 5, 35, 36 Comparative analyses between 18 F-DOPA and 18 F-FDG have shown better results with 18 F-DOPA in terms of sensitivity and specificity and a complementary role of the two radiopharma- 5, 25, 37, 38 The different behaviour of 18 F-DOPA and 18 F-FDG in recurrent MTC can be explained by their different uptake mechanisms that, in turn, reflect the different metabolic pathways of NET cells, including MTC 18 F-DOPA is a marker of amino acid decarboxylation which is a feature of the neuroendocrine 18 F-DOPA uptake is related to a higher degree of cell differentiation, 5,16 whereas a higher 18 F-FDG uptake is related to a high-proliferative activity and a poor 5, 14 Although 18 F-DOPA PET/CT has less prognostic value compared to 18 F-FDG, it can more accurately assess the extent of the disease in patients with residual/recurrent MTC, 5,38 particularly 39, 40 Comparative analyses between somatostatin analogues labelled with Gallium-68 and 18 F-FDG have shown the complementary role of these PET tracers in recurrent MTC without statistically significant difference in terms of detection rate of MTC lesions in the [23] [24] [25] [26] 29 Some limitations of our meta-analysis should somatostatin receptor PET in patients with recurrent MTC is still limited (only nine studies were included in the quantitative analysis) and this could limit the Heterogeneity between studies may represent a This heterogeneity is likely to arise through the diversity of methodological aspects of the different the patients in the included studies (Table 1) and the study quality (Table 4) may also have contributed to such variability was accounted for in a random ef-19 Furthermore, performing the sub-analysis taking into account the serum Ctn values we found a significant reduction of heterogeneity (I 2 Publication bias is a major concern in all forms of meta-analyses, as studies reporting significant findings are more likely to be published than those unusual for small-sized early studies to report a positive relationship that subsequent larger studies fail We chose to calculate the DR on a per patient-based analysis because most of the authors have adopted this bias derived from this choice, but there were insufficient data to obtain significant results performing was not possible to perform a sub-analysis compar-
CONCLUSIONS
Overall our systematic review and meta-analysis showed that: -The literature focusing on the use of somatostatin receptor PET in recurrent MTC is still limited and -In patients with recurrent MTC somatostatin receptor PET or PET/CT demonstrated a non-optimal DR which increased in patients with higher serum -The diagnostic performance of somatostatin receptor PET or PET/CT in recurrent MTC is lower compared to that of the same imaging method in -According to recent international guidelines, somatostatin receptor PET/CT should not be a first option for detecting recurrent MTC; however, it could be useful in a minority of patients with recurrent MTC, mainly when neither 18 F-DOPA nor 18 F-FDG-PET/CT are conclusive in patients with increasing Ctn levels and negative conventional imaging methods or when treatment with
